Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: BTH post# 121232

Tuesday, 06/07/2011 9:42:26 PM

Tuesday, June 07, 2011 9:42:26 PM

Post# of 257580
Two points:

(1) Has it even been tested yet in patients who are not positive for EML4-ALK? How do we know that crizotinib's efficacy is limited to these patients?

(2) My main point is not that ALK is not a valid target, but when you have a drug that is targeting multiple pathways how exactly do you know how much antitumor activity is attributable to each pathway?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today